Fundación Bamberg’s Post

Today is the Alimentiv Translational Research Consortium (ATRC) Symposium! This years symposium is focused on all aspects of combination therapy for #IBD, with fantastic presentations planned about clinical efficacy and safety, pharmacology, translational medicine, and drug design and development. #translationalresearch #IBDresearch #precisionmedicine

I am pleased to share our recently published manuscript, as part of the precision medicine working group of the Crohn's & Colitis Foundation "Challenges in IBD Research 2024: Precision Medicine" https://lnkd.in/ez3ybbPv This comprehensive document highlights significant gaps in inflammatory bowel disease (IBD) research and offers actionable strategies to address them. Grateful for the opportunity to be part of this multidisciplinary collaboration that made this work possible! "Precision medicine is the practice of getting the most suitable drug or treatment option to each individual patient at the right time. In Crohn’s disease and ulcerative colitis, we need to learn more about the diversity of patients to deliver precision medicine." #IBDResearch #PrecisionMedicine #Biomarkers #CrohnsAndColitisFoundation #HealthcareInnovation

📣 Exciting milestone achieved!  We are thrilled to announce we've dosed the first patients suffering from acute ischemic stroke in our Phase 2 clinical trial, RAISE!   Did you know over 80% of ischemic stroke patients don't receive any acute intervention?    Our novel treatment, BB-031, is designed to reopen blocked vessels in an expanded treatment window of up to 24 hours post stroke onset to address this tremendous unmet need.   Huge congratulations to Mouhammad Jumaa MD, FSVIN, FAHA and the incredible clinical research team at ProMedica Toledo Hospital for your vital role in achieving this milestone. Thank you for your unwavering commitment to advancing patient care! 👏   "ProMedica Toledo hospital was the highest enrolling site in the TIMELESS trial which explored the use of lytics in a similar time window," said Dr. Jumaa. "Now we're focused on RAISE to expand medical non-interventional treatment options for ischemic stroke patients beyond the conventional time window, where treatment options remain limited. This is especially true for patients who don’t have immediate access to mechanical thrombectomy. RAISE offers hope for improved patient outcomes." RAISE Site Principal Investigator and the Director of Neurointervention Syed Zaidi, MD added, "Being a leader in clinical trials allows us to rigorously test novel therapies like those from Basking Biosciences that we believe will benefit all stroke patients." Learn more: rb.gy/t8niwf   #drugdiscovery #RNA #aptamers #thrombolytics #vonWillebrandFactor #vWF #stroke #clinicaltrials #ClinicalResearch #Phase2 #MakingADifference

How can we improve outcomes for patients with #liverdisease in the UK? 👉 https://lnkd.in/dkg42TwU to read our full review, published in Frontline Gastroenterology. In the last 5 years, recruitment to #clinicaltrials has significantly dropped across the UK with our global ranking falling from 4th to 10th. It is well documented that patients with liver disease are underserved. Developing new treatments that improve the outcome for this patient group remains an unmet area of clinical need. We're a #CRO in #hepatology and delighted to have collaborated with the UK hepatology community including Oliver Tavabie, Gautam Mehta, Rajiv Jalan, Daniel Green and the UK-Chronic Liver Failure network (UK-CLIF), on a review discussing the challenges and opportunities for innovating #hepatologytrials in the UK, with a focus on improving clinical trial performance and access to #innovative therapies for patients with decompensated #cirrhosis. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY ⇒ We propose a number of innovations in clinical trial design to improve access to clinical trials for patients, clinicians and investigators alike. ⇒ We highlight the importance of agreeing and implementing standards of care for this patient group, which should not just improve clinical outcomes but reduce heterogeneity in standard of care/placebo cohorts. ⇒ We discuss the potential role of collaboration with industry to improve the delivery of clinical trials. ⇒ We discuss the importance of ensuring the development of the next generation of investigators to ensure sustainability to this model of working. You can read the full review on the PHARMExcel website 👉 https://lnkd.in/dkg42TwU #Gastroenterology #FrontlineGastroenterology #ClinicalResearch Footnote: Image represents an overview of recommendations and themes from the O’Shaughnessy report, NHS. ©️PHARMExcel

🚀 Exciting News in the World of Cardiovascular Health! 🚀 I am thrilled to share a groundbreaking report recently published by the American Heart Association. This comprehensive study highlights new advancements and insights into cardiovascular health, paving the way for innovative approaches in personalized medicine. 🔗 Check out the full report here: Read the Report https://lnkd.in/gpM-4DMn One key takeaway from this report is the critical importance of taking a multi-factorial approach to cardiovascular health. By considering various factors such as genetics, lifestyle, and environmental influences, healthcare providers can offer more comprehensive and effective care. Clinical Decision Support (CDS) systems are instrumental in this approach, as they analyze vast amounts of data to provide healthcare professionals with actionable insights. At GenXys, we are committed to integrating multiple patient factors into our CDS solutions. Our software is designed to empower clinicians with precise, data-driven, and personalized healthcare insights, ensuring that each patient receives the most effective and tailored treatment. This report reinforces the importance of our mission to deliver advanced CDS solutions that enhance patient care and optimize treatment strategies through a multi-factorial lens. #CardiovascularHealth #MultiFactorialApproach #ClinicalDecisionSupport #PersonalizedMedicine #HealthcareInnovation #GenXys #AHA #NewResearch #HealthTech #MedicalAdvancements

🌟 New Diagnostic Tool for Demyelinating Neuropathies from Mayo Clinic Laboratories 🌟 At Mayo Clinic Laboratories, we continually strive to deliver expert-backed testing that helps physicians better diagnose and treat complex conditions. Our latest offering, the Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation (DMNES) test, is designed to provide more accurate diagnosis for conditions like: - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Guillain-Barré Syndrome (GBS) - Autoimmune Nodopathy, and more 🔑 Key Advantages: - Helps differentiate between disease etiologies in patients with demyelinating neuropathy - Detects 7 specific antibodies aligned with electrophysiological findings - Results guide prognosis, treatment decisions, and aid in searching for underlying hematological cancers - Our report includes detailed interpretive comments for physicians Listen to the Experts: In our latest "Answers From the Lab" podcast, Dr. John Mills and Dr. Divyanshu Dubey explain how this new test can help identify the specific cause of demyelinating neuropathies and guide personalized treatment for rapidly progressing autoimmune conditions. 🔗 Tune in to learn more: Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. - Insights (mayocliniclabs.com). Feel free to connect if you're interested in exploring this groundbreaking diagnostic tool or learning more about how Mayo Clinic Laboratories is advancing patient care! #Neurology #DemyelinatingNeuropathy #CIDP #GBS #AutoimmuneNeurology #healthcare #MayoClinicLaboratories #ClinicalDiagnostics

🟡 New article in DIA Read our article in this month's DIA magazine on the patient-focused approach we have taken to developing our diagnostic TPP document. We have incorporated crucial input from people with Cystic Fibrosis from the outset and throughout. Engaging people with lived experience early in TPP development provides invaluable insights into real-world experiences, unmet needs and preferences that can't be found in textbooks or databases. Read here: https://ow.ly/ccgT50Tj4eQ Medicines Discovery Catapult | Cystic Fibrosis Trust | LifeArc NIHR HRC in Diagnostic and Technology Evaluation #CysticFibrosis #AMR #TPP

In the realm of healthcare, breakthroughs are crucial for tackling severe conditions like septic shock. Vivacelle Bio, Inc. is revolutionizing this space with innovative strategies highlighted in a recent interview with Harven DeShield, PhD, JD, MSc. Here are the key insights: - VivaCell's treatment approaches aim to enhance patient outcomes in septic shock care. - The focus is on improving cellular health to combat sepsis's severe impacts. - The company is leading with new methods that could potentially lower mortality rates linked to septic shock. - Innovative techniques address current treatment challenges and limitations effectively. - Ongoing clinical trials are yielding promising results, marking a significant advancement in septic shock management. #HealthcareInnovation #SepticShock #ClinicalTrials #Biotechnology #PatientCare #MedicalResearch #HealthTech https://lnkd.in/dUitYDHU

Understanding SPMS: Insights from Dr. Jiwon Oh #Diagnosing multiple sclerosis (MS) can be an incredibly complex process for both #patients and #doctors. With symptoms that often overlap with, or mimic other conditions, making a definitive #diagnosis is challenging and could potentially take months or even years. Advancements in research are essential for improving diagnostic accuracy and enabling earlier intervention, which can significantly enhance the quality of life for individuals living with MS. In this episode, sponsored by Sanofi, we have the privilege of speaking with Dr. Jiwon Oh, a distinguished neurologist, scientist, and Medical Director of the BARLO Multiple Sclerosis (MS) Centre at St. Michael’s Hospital, University of Toronto. Dr. Oh is also the principal investigator for several key studies, including the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) that aims to deepen our understanding of MS progression. Today, she delves into the complexities of secondary progressive MS (SPMS), discussing everything from the need to reassess its various subtypes to the importance of clinical trials focusing on non-relapsing SPMS patients. “The significance of a trial that focuses exclusively on non-relapsing SPMS is that there have been very few trials looking at progressive MS in general,” Dr. Oh explains, outlining how progress is now starting to be made in this field. https://lnkd.in/dti2fVBu

Treatment options for IBD have expanded in the last two decades, but it isn’t enough. We need fewer insurer-mandated barriers to truly improve the care of patients with IBD. That’s why we’re leading the future of IBD care by identifying barriers to remove and opportunities to explore in our 12-point plan. This white paper, published in AGA’s Clinical Gastroenterology and Hepatology journal, proposes tangible solutions to provide patients with high quality, high value care. Learn more: https://ow.ly/QkOE50QM1Mg Read the white paper: https://ow.ly/r27U50QM1Mf